A new redox-sensitive micellar system consisting of hyaluronic acid (HA)-based amphiphilic conjugate (HA-ss-(OA-g-bPEI), HSOP) was formulated for tumor-based codelivery of paclitaxel (PTX) and AURKA-explicit siRNA (si-AURKA) for the treatment of targeted cancer therapy. This evidence concerns the gene AURKA and neoplasm.